Funding (Updated 09/24/2014)

Funding (Updated 09/24/2014)

External Funding Opportunities​​

2015 NSF Major Research Instrumentation Program 


The Major Research Instrumentation Program (MRI) serves to increase access to shared scientific and engineering instruments for research and research training in our Nation's institutions of higher education, not-for-profit museums, science centers and 1scientific/engineering research organizations. The program provides organizations with opportunities to acquire major instrumentation that supports the research and research training goals of the organization and that may be used by other researchers regionally or nationally.

LIMITED SUBMISSIONS (pease see policy at right)
UAB may submit up to 3 applications, each requesting $100K-$4M, and in the event that 3 are submitted (any applications for which UAB is included as a “significantly funded” subawardee counts as 1), one of them must be an instrumentation development application. In order to allow sufficient time for an internal review, and to give the successful PIs as much time to write the proposal as possible, please submit a 3 page summary of the project with a separate page detailing plans for matching support (30% of total costs) and a biosketch of the PI(s)by COB on November 10th to Dr. Kent Keyser (ktkeyser@uab.edu). 

    Internal Deadline: COB, November 10th, to ktkeyser@uab.edu
    Letter of Intent Due Date: None
    Application Due Date: January 22, 2015
   

NIH Director's Early Independence Awards 

     DP5       RFA-RM-14-004

The NIH Director’s Early Independence Award Program supports exceptional investigators who wish to pursue independent research directly after completion of their terminal doctoral/research degree or clinical residency, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career.   

    Letter of Intent Due Date: December 30, 2014
    Application Due Date: January 30, 2015​, 5pm CT

Rita Allen Foundation Scholars Program

     RFA

The Rita Allen Foundation Scholars program supports basic biomedical research in the fields of cancer, immunology and neuroscience. There also is currently a joint award for scholars in pain research, which is sponsored by the Rita Allen Foundation and the American Pain Society.  

UAB has been invited to nominate one (1) individual to apply for this award.  If you meet the eligibility criteria and wish to be considered, please submit your biosketch by email to Kent T. Keyser, PhD (ktkeyser@uab.edu), Assistant Vice President for Research, with Rita Allen Scholars in the subject line stating your interest by close of business  Friday, October 24.  Please see sidebar for UAB's policy when number of submissions is limited by sponsor.

    Internal Deadline: 5pm, October 24, 2014
   
Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia 
R01 PA-15-017 
R21 PA-15-015  
R15 PA-15-016
The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimer’s disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers.   

    Letter of Intent Due Date: None
    Application Due Date: Standard (until January 8, 2018)

Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities 

This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications that propose to develop    a product, process or service for commercialization with the aim of reducing disparities in healthcare access and health outcomes.  Appropriate technologies should be effective, affordable, culturally acceptable, and deliverable to racial/ethnic minorities, low-income and rural populations.  

    Letter of Intent Due Date: December 27, 2014
    Application Due Date: January 27, 2015, 5pm

Building Interdisciplinary Research Careers in Women's Health 

The NIH Office of Research on Women's Health (ORWH) and its cosponsors invite institutional career development award applications for Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Career Development Programs, hereafter termed "Programs." Programs will support mentored research career development of junior faculty members, known as BIRCWH Scholars, who have recently completed clinical training or postdoctoral fellowships, and who will be engaged in interdisciplinary basic, translational, behavioral, clinical, and/or health services research relevant to women's health, and where appropriate the use of both sexes to better understand the influence of sex as a variable on health and disease.  

    Letter of Intent Due Date: December 5, 2014
    Application Due Date: January 5, 2015, 5pm​

Children's Environmental Health and Disease Prevention Research Centers 

     P50     RFA-ES-14-002

This Funding Opportunity Announcement (FOA) encourages grant applications to support a transdisciplinary program of basic and applied research to examine the effects of environmental factors on children’s health and well-being. Research conducted through the Centers should include substantive areas of science in children’s health while incorporating innovative technologies and approaches and links to the environment. This program encourages strong links between disciplines in the basic, applied, clinical and public health sciences to prevent disease and promote health of all children.     

    Letter of Intent Due Date: November 22, 2014
    Application Due Date: December 22, 2014

Hepatitis C Cooperative Research Centers: Immunity to HCV Infection 
     U19 RFA-AI-14-045​

The purpose of the Funding Opportunity Announcement (FOA) is to support research on the host immunological response to Hepatitis C Virus (HCV) infection with the goal of defining the immune requirements critical to a) protection against HCV infection, and b) successful clearance of HCV infection, conducted through Hepatitis C Cooperative Research Centers (HepC Center(s)).  

    Letter of Intent Due Date: January 2, 2015
    Application Due Date: February 3, 2015, 5pm CT

Self-Management for Health in Chronic Conditions 
     R01 PA-14-344
     R15 PA-14-345
     R21 PA-14-343
The purpose of this initiative is to support research in self-management focused across conditions. A recent report from the Institute of Medicine (IOM) identifies the epidemic of chronic condition as the nation’s leading health challenge and calls for cross-cutting, coordinated public health actions for “living well with chronic illness”.  This Funding Opportunity Announcement (FOA) addresses that recommendation by describing an initiative that focuses on self-management as a mainstream science in order to reduce the burden of chronic illnesses / conditions. Self-management is the ability of the individual, in conjunction with family, community, and healthcare professionals, to manage symptoms, treatments, lifestyle changes, and psychosocial, cultural, and spiritual consequences associated with a chronic illness or condition.   

    Letter of Intent Due Date: none
    Application Due Date: Standard dates apply (until 01/18/2018)
 
Analyses of Datasets on Older Populations with High Prevalence of Mobility Disability to Develop Clinically Meaningful Diagnostic Cut-Points for Low Muscle Mass and/or Low Muscle Strength

     U01     RFA-AG-15-013​

This initiative invites applications for support of analyses of existing data (or data whose collection will be completed by one year from the date of this FOA) from older populations with high prevalence of mobility disability, low muscle mass, and low muscle strength (weakness).  Interventions targeted at low muscle mass and/or weakness may prevent or reduce mobility disability in some older persons.  To assess the efficacy of such interventions against mobility disability, there is a need to test them in persons in whom muscle mass and/or strength are (or will be) sufficiently low to be likely contributors to disability.  Thus there is a need for evidence-based diagnostic cut-points to define target populations for treatments.  See RFA for more details.


    Letter of Intent Due Date: December 15, 2014
    Application Due Date: 5pm, January 15, 2015
 ​
Gut-Microbiome-Brain Interactions and Mental Health 
     R21/R33     RFA-MH-15-850     Phased Innovation Award

This Funding Opportunity Announcement (FOA) encourages research grant applications from institutions/organizations to investigate mechanisms by which the gut microbiome modulates the development and function of brain circuits that subserve behavioral functions of direct relevance to the mission of the NIMH.  Because initial colonization of the gut by microbiota occurs early in life and may influence the subsequent development and modifiability of the central nervous system, developmental studies are of interest. Applicants may propose to use wild-type, gnotobiotic, and/or specific pathogen-free model organisms. With this FOA, the NIMH encourages investigator teams to initiate hypothesis-driven research in this cross-cutting research area and to identify promising mechanistic leads for future basic and translational research that will advance the mission of the NIMH. 

    Letter of Intent Due Date: October 25, 2014
    Application Due Date: 5pm, November 25, 2014

Epigenetic Analyses of Aging as a Risk Factor for Multiple Chronic Conditions 
     U34     RFA-AG-15-004

The emergent field of geroscience seeks to relate the biology of aging to the development of chronic diseases and the onset of degenerative conditions which are prevalent in the older segment of human populations. It is generally accepted that age is the major risk factor for most chronic diseases and degenerative conditions in adults. Thus, a critical question in geroscience is to identify components in the biology of aging that are the underlying risk for multiple chronic diseases and degenerative conditions. Therefore, this FOA will support planning grants to circumscribe the scope of this question and suggest ways to answer it experimentally. The focus will be on epigenetics underlying aging as a risk factor for age-related diseases and degenerative conditions in humans. Mortality and age-related mortality are outside the scope of this FOA. Studies using model organisms are outside the scope of this FOA.

    Letter of Intent Due Date: December 15, 2014
    Application Due Date: 5pm, January 15, 2015

Advancing Interventions to Improve Medication Adherence 
     R21 PA-14-335
     R01 PA-14-334​

This funding opportunity announcement (FOA) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR), with participation from multiple NIH Institutes and Centers. This FOA seeks Research Project Grant (R01) applications that propose interventions to significantly improve medication adherence in individuals. Applications may target medication adherence in the context of treatment for a single illness or chronic condition (e.g., hypertension), to stave off a disease recurrence (e.g., cancer) or for multiple comorbid conditions (e.g., hypertension, diabetes, alcohol use disorders and HIV/AIDS). A well-articulated theoretical or conceptual framework is key for applications encouraged under this announcement. Primary outcomes of the research can include a patient self-report of medication adherence, but must also at least one non-self-report measure of medication adherence (e.g., pharmacy refill records, electronic monitoring, etc.). In addition, applications are encouraged to include a relevant health outcome or biomarker (e.g., blood pressure, viral load in HIV-infected individuals, cholesterol levels, HbA1c) that is expected to be affected by changes in the targeted adherence behavior. For diseases without identified biomarkers, inclusion of a clinical assessment (e.g., a medicine blood level, diagnostic interview or an independent clinician rating of the symptoms and behaviors) may be considered. 

    Letter of Intent Due Date: None
    Application Due Date: Standard NIH Deadlines (until 01/08/2018)


NSF Computer Systems Research (CSR) Program​
Computer and Network Systems (CNS): Core Programs (RFA)
  • Computer Systems Research (CSR): Core Area and Highlighted Areas
  • Networking Technology and Systems (NeTS) : Core Area and Highlighted Areas
Information and Intelligent Systems (IIS): Core Programs (RFA
  •      Cyber-Human Systems (CHS)
  •      Information Integration & Informatics (III) (RFA2)
  •      Robust Intelligence (RI)
Computing and Communication Foundations (CCF): Core Programs (RFA)
  •      Algorithmic Foundations (AF)
  •      Communications and Information Foundations (CIF)
  •      Software and Hardware Foundations (SHF)
The Computer Systems Research (CSR) program supports transformative research in computer systems including:  multi-core architectures, operating systems, middleware and run-time support systems, programming models and tools, storage and file systems, hybrid and embedded systems, web-based systems, datacenters, distributed systems, parallel systems, large scale grids, wireless systems, mobile systems, and sensor systems. 

    Letter of Intent Due Date: None
    Application Due Date: See RFA

Research Planning Infrastructure to Develop Therapeutic Target-ID Strategies Based on Favorable Genetic Variants of Human Longevity or Health Span (U24) 

     RFA-AG-15-014  

This FOA invites applications for a project for the development of a research planning infrastructure by a multidisciplinary collaborative team to develop target identification (ID) strategies based on effects of genetic factors reliably associated with increased human lifespan and/or health span. The phrase "target ID strategy" refers to a concerted set of applied research approaches (e.g., additional analyses, conducting required types of studies/ experiments and methodologies in the appropriate sequence) leading to the identification of genetic factors, pathways, or molecules by which activities could be favorably modified. Planning activities to be conducted by the U24 project include the creation of an integrated database of relevant data, informatics and computational tools for assessing the effects of favorable gene variants, evaluating their potential utility for developing therapeutic ID strategies, developing plans for experiments and analyses aimed at identifying one or more therapeutic target(s) and establishing a publicly available resource. Core areas of expertise which should be represented in the U24 multidisciplinary team include genetics, genomics, epidemiology, aging research, translational genomics, drug development, statistics, and bioinformatics. 

    Letter of Intent Due Date: October 6, 2014
    Application Due Date: November 6, 2014 by 5PM CT

Bioreactors for Reparative Medicine 
     R41/R42     RFA-HL-15-004
     R43/R44     RFA-HL-15-008  
     R44            RFA-HL-15-017

Major obstacles to the generation of functional tissues and their widespread use are limited by rudimentary tissue growth technologies. The purpose of this funding opportunity is to encourage small businesses to develop sophisticated and complex biomimetic culture systems that are capable of precise control of the cellular and 3-dimensional organ microenvironment, and which address the unique physiological dynamics of heart, lung and blood tissues.  Projects awarded under this announcement should show evidence of developing or using good laboratory practice (GLP) standards and/or good manufacturing practices (GMP) standards, which play an important role in the adoption of many technologies used for pre-clinical research.  Additionally, sources of cell variability should be discussed in the context of potential elements of measurement assurance and use of reference materials.  For projects proposing clinical grade bioreactors and clinical investigations, an applicant must provide evidence that they have contacted the Food and Drug Administration (FDA) for guidance concerning the development of their bioreactor device, such as correspondence regarding Investigational New Drug (IND) Application and status of their project in a timeline related to Federal regulatory approval processes. 

    Letter of Intent Due Date: 30 days before deadline
    Application Due Date: October 10 or April 14 by 5pm
                                           (until 04/15/2016) CT

Platform Delivery Technologies for Nucleic Acid Therapeutics 
     R43/R44 PA-14-307
     R41/R42 PA-14-308

The purpose of this initiative is to incentivize small businesses to generate new technologies and products for  delivering nucleic acids  into cells and tissues for the purpose of treatment or prevention of human disease.   

    Letter of Intent Due Date: None
    Application Due Date: Standard deadlines (until September 8, 2016)​


Testing Interventions for Health-Enhancing Physical Activity 
     R01; PAR-14-315
The purpose of this Funding Opportunity Announcement (FOA) is to fund highly innovative and promising research that tests multi-level intervention programs of 1 to 2 years in length that are designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation.  This FOA provides support for up to 5 years for research planning, intervention delivery, and follow-up activities.  

    Letter of Intent Due Date: None
    Application Due Date: See RFA (until September 8, 2017)


Developing Interventions for Health-Enhancing Physical Activity 
      R21/R33; PAR-14-321

This Funding Opportunity Announcement (FOA) encourages applications for Phased Innovation (R21/R33) grant awards to support highly innovative research aimed at developing multi-level interventions that will increase health-enhancing physical activity: 1) in persons or groups who can benefit from such activity; and 2) that can be made scalable and sustainable for broad use across the nation.  This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by a possible transition to expanded research support (R33 phase). Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds.  

    Letter of Intent Due Date: None
    Application Due Date: See RFA (until September 8, 2017)


Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care 
     R01 PA-14-312
     R03 PA-14-313
     R21 PA-14-311​

This funding opportunity announcement (FOA) encourages a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in the intensive care units. The FOA welcomes applications related to (but not limited to): the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional levels to help reduce and eliminate medical errors. It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness.     

    Letter of Intent Due Date: 30 days before the deadline
    Application Due Date: Standard dates apply (until September 8, 2017)


NINDS CREATE Devices:

Translational and Clinical Studies to Inform Final Device Design 
  PAR-14-300  U44 SBIR Cooperative Agreement – Fast-Track
  PAR-14-297  UH2/UH3 Phase Innovation Awards Cooperative Agreement


Translational and Early Feasibility Studies on the Path to Pre-Market Approval (PMA) or Humanitarian Device Exemption (HDE)  
  PAR-14-298  UH2/UH3 Phase Innovation Awards Cooperative Agreement
  PAR-14-299​  U44 SBIR Cooperative Agreement – Fast-Track

Translational and Clinical Studies on the Path to 510(k) 
  PAR-14-296  U44  SBIR Cooperative Agreement – Fast-Track
  PAR-14-295​  UH2/UH3 Phase Innovation Awards Cooperative Agreement

The purpose of these Funding Opportunity Announcements (FOA) is to encourage applications to pursue translational and Early Feasibility Studies for therapeutic devices to treat neurological disorders. The program will utilize a cooperative agreement mechanism to support the submission of an Investigational Device Exemption (IDE), with the option of also supporting the following Early Feasibility Study.   It is expected the immediate next steps upon completion of the Early Feasibility Study will be a full Feasibility Study and a Pivotal Trial in support of a PMA (Pre-Market Approval) or HDE (Humanitarian Device Exemption). Activities supported in this program include implementation of clinical prototype devices, preclinical safety and efficacy testing, design verification and validation activities, pursuit of regulatory approval for the clinical study, and an Early Feasibility Study.   

    Letter of Intent Due Date: None
    Application Due Date: See RFA (until May 8, 2017)

AHRQ Health Services Researc
    Demonstration and Dissemination Grants   R18    PA-14-290  
    Research Projects   R01    PA-14-291​  

The Research Demonstration and Dissemination Grant (R18) is an award made by AHRQ to an institution/organization to support a discrete, specified health services research project. The project will be performed by the named investigator and study team. The R18 research plan proposed by the applicant institution/organization must be related to the mission and priority research interests of AHRQ. 

    Letter of Intent Due Date: Not applicable
    Application Due Date: Standard dates apply 
       (until May 26, 2017 for R18; until July 6, 2017 for R01)


Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System 

    UH2/UH3 (SBIR/STTR)   PAR-14-293  
    U44 (Cooperative Agreement)  PAR-14-292

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize well-validated hit compounds through medicinal chemistry, or at the Development stage, to advance development candidates through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN participants receive intellectual property rights to drug candidates developed through the program.  

    Letter of Intent Due Date: 30 days before deadline
    Application Due Date: See RFA (until May 8, 2017)


2015 PhRMA Research and Training Awards 


Health Outcomes Application Deadline : 02-01-2015
Clinical Pharmacology Application Deadline : 02-01-2015 Translational Medicine and Therapeutics Application Deadline : 02-01-2015

The PhRMA Foundation funds scientists at critical points in their research careers to support and reward innovation in disciplines essential to the development of safe and effective medicines. The PhRMA Foundation offers competitive pre and post doctoral fellowships, sabbatical fellowships, and research starter grants to advance science in Adherence Improvement, Clinical Pharmacology, Comparative Effectiveness Research, Health Outcomes, Informatics, Pharmaceutics, Pharmacology/Toxicology, and Translational Medicine and Therapeutics.

High Throughput Screening (HTS) to Discover Chemical Probes

     PAR-14-283            R21
     PAR-13-134      X01 
     PAR-13-135      R03
     PAR-14-284      R01 

These Funding Opportunity Announcements (FOAs) encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatments relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms.  Emphasis will be placed on projects that provide new insight into important disease targets and processes. 

    Letter of Intent Due Date: 30 days prior to deadline
    Application Due Date: Standard dates apply (until 09/08/17)​


Ethical, Legal, and Social Implications (ELSI) of Genomic Research
    Exploratory/Developmental Research Program (R21)  PA-14-278    
    Regular Research Program (R01)    PA-14-276
    Small Research Grant Program (R03)    PA-14-277    

This Funding Opportunity Announcement (FOA) invites Exploratory / Developmental Research Program Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research.  Applications should propose exploratory or developmental studies that break new ground or extend previous discoveries in new directions.  Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information. 

    Letter of Intent Due Date: Not applicable
    Application Due Date: Standard NIH deadlines apply (until 09/08/17) 

 
Discovery of in vivo Chemical Probes (R01)


This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes. It is expected that applicants will have in hand the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms.  Emphasis will be placed on projects that provide new insight into important disease targets and processes. 

    Letter of Intent Due Date: 30 days prior to due date
    Application Due Date: Standard NIH deadlines apply (until 09/07/17) 


Translational Research to Help Older Adults Maintain their Health and Independence in the Community

R21: PA-14-159 (link)

R01: PA-14-161 (link)

This Funding Opportunity Announcement (FOA) invites applications using the R01 award mechanism for translational research that moves evidence-based research findings toward the development of new interventions, programs, policies, practices, and tools that can be used by organizations in the community to help older adults remain healthy and independent, productively engaged, and living in their own homes and communities.  The goal of this FOA is to support translational research involving collaborations between academic research centers and community-based organizations with expertise serving or engaging older adults (such as city and state health departments, city/town leadership councils, educational institutions, workplaces, Area Agencies on Aging, and organizations funded or assisted by the Corporation for National and Community Service) that will enhance our understanding of practical tools, techniques, programs and policies that communities across the nation can use to more effectively respond to needs of the aging population. 

    Letter of Intent Due Date: Not applicable
    Application Due Date: Standard dates by 5PM CT (until May 8, 2017)


Biomedical Technology Research Resource (P41)
   PAR-14-023      Pre-Application
   PAR-14-021​   Full Proposal

This funding opportunity announcement (FOA) encourages grant applications for national Biomedical Technology Research Resources. These Resources conduct research and development on new technologies and new/improved instruments driven by the needs of basic, translational, and clinical researchers. The Resources are charged to make their technologies available, to train members of the research community in the use of the technologies, and to disseminate these technologies and the Resource’s experimental results broadly. New applicants are strongly encouraged to submit a pre-application to PAR-14-023. The pre-application process provides feedback regarding the appropriateness for this program and competitiveness of a potential application.

    Letter of Intent Due Date: Not applicable
    Application Due Date: Sep 25, 2014; Jan 25, 2015; May 25, 2015; 
    Sep 25, 2015; Jan 25, 2016; May 25, 2016; Sep  25, 2016, by 5:00 PM​

Assessment of Prevention, Diagnosis, and Treatment Options – Fall 2014 Cycle


PCORI is seeking applications for comparative effectiveness research designed to provide information that would inform critical decisions that face patients and caregivers, clinicians, policy makers, and health care system leaders. These decisions must be consequential and be occurring now in the absence of sound evidence about the comparative effectiveness of alternative approaches. There must be substantial potential that patients/caregivers will benefit from the new knowledge in ways that are important to them. The premise of this research is that the new knowledge will inform critical choices by patients and stakeholders in health care. This knowledge will provide insight about the comparative benefits and harms of the options and provide information about outcomes that are important to patients.

    Letter of Intent Due Date: 09/05/2014
    Application Due Date: 11/04/2014 by 5:00 PM ET​


Improving Healthcare Systems – Fall 2014 Cycle


PCORI is seeking applications to study the comparative effectiveness of alternate features of healthcare systems (e.g., innovative technologies, personnel deployments, incentives, service designs) designed to optimize the quality, outcomes, and/or efficiency of care for the patients they serve. Healthcare systems include private and public health insurance plans; physician groups; hospitals, nursing homes and assisted living facilities; academic medical centers; integrated delivery systems; community-based and safety-net clinics; federal, state, and municipal providers; and other entities organized to deliver, arrange, purchase, or coordinate healthcare services. PCORI seeks studies that will provide information of value to patients, their caregivers, and clinicians, as well as to healthcare leaders, regarding which features of systems lead to better patient-centered outcomes. 

    Letter of Intent Due Date: 09/05/2014
    Application Due Date: 11/04/2014 by 5:00 PM ET​

Communication and Dissemination Research – Fall 2014 Cycle


PCORI seeks to fund projects that address critical knowledge gaps in the communication and dissemination process—both the communication and dissemination of research results to patients, their caregivers, and clinicians, as well as the communication between patients, caregivers, and clinicians in the service of enabling patients and caregivers to make the best possible decisions in choosing among available options for care and treatment.

    Letter of Intent Due Date: 09/05/2014
    Application Due Date: 11/04/2014 by 5:00 PM ET​


Addressing Disparities – Fall 2014 Cycle

In this PCORI Funding Announcement (PFA), we seek to fund comparative effectiveness research (CER) studies that evaluate and compare new and/or enhanced interventions to reduce or eliminate disparities in health and health care. Studies in the Addressing Disparities program should focus on overcoming barriers that may disproportionately affect the outcomes of specific groups of patients, or identify best practices for sharing results and information about patient-centered research across patient groups.
    Letter of Intent Due Date: 09/05/2014
    Application Due Date: 11/04/2014 by 5:00 PM ET​

Improving Methods for Conducting Patient-Centered Outcomes Research – Fall 2014 Cycle


In this PCORI Funding Announcement (PFA), we seek projects to address gaps in methodological research relevant to conducting patient-centered outcomes research (PCOR). Results of these projects will inform future iterations of PCORI’s Methodology Report. The improvement of existing methods will benefit all stakeholders, including researchers planning investigations, policy makers weighing the value of healthcare interventions, and patients, clinicians, and caregivers facing healthcare decisions.

    Letter of Intent Due Date: 09/05/2014
    Application Due Date: 11/04/2014 by 5:00 PM ET​

    
Onsite Tools and Technologies for Heart, Lung, and Blood Clinical Research Point-of-Care SBIR 

R43/R44 RFA-HL-14-011

The purpose of this Funding Opportunity Announcement (FOA) is to support research using advanced technologies to develop novel point-of-care (POC) devices and implement existing technologies in clinical settings with a goal to guide diagnostic and therapeutic efforts for the heart, lung, blood (HLB) and sleep disorders. 

Budget
R43/R44 and R41/R42:   Budget: Budgets up to $225,000 total costs for Phase I and up to $1,500,000 total costs for Phase II may be requested. 

    Letter of Intent Due Date(s)
     R43/R44 Sept.15, 2014; March 16, 2015; Sept. 15, 2015 
     R41/R42 Not applicable

     Application Deadline(s)
     ​R43/R44 Oct.15, 2014; April 16, 2015; Oct.15, 2015;by 5PM
     R41/R42 Oct. 15, 2014; Oct.15, 2015, Oct.15, 2016, by 5PM



Alabama Launchpad Small Business Innovation Research(SBIR) and the Small Business Technology Transfer Programs

Administered by the US Small Business Administration, through which many of the largest federal agencies award contracts and grants to small businesses.  The purpose of the Alabama SBIR/STTR Support Program is to increase the success rate and competitiveness of SBIR/STTR applicants in the state. The program will provide support in three ways:

  1. Raise SBIR/STTR awareness for Alabama-based small businesses through a statewide network of partners that will advocate and host introductory SBIR/STTR workshops

  2. Educate Alabama companies on how to compete for SBIR/STTR awards

  3. Provide one-on-one writing assistance and proposal strategy from an expert with decades of experience writing and reviewing SBIR/STTR proposals

Benefits

  • Beyond-the-basics training about SBIR and STTR Programs

  • How to prepare competitive proposals and proposal strategy

  • Avoiding common proposal mistakes

  • Federal agency focused workshops

  • Proposal evaluation

  • Individual writing assistance

Applicants can receive extensive proposal writing assistance for a chance to receive over $1 million in SBIR/STTR funding. Click here for more info.

Sponsor: Alabama SBIR/STTR Support Program

Letter of Intent: None

Application Deadline: Rolling

RFA:  AL SBIR/STTR


Community Partnerships to Advance Research (CPAR)

R21: PA-14-141,  Exploratory/Developmental Grant

R01: PA-14-142,  Research Project Grant   

R15: PA-14-140,  Academic Research Enhancement Award (AREA)

This funding opportunity announcement (FOA) encourages researchers to partner with communities using Community Engaged Research (CEnR) methodologies that will enhance relationships leading to better interventions and positive health outcomes.     Research objectives aim to partner with a community entity on health issues that is of mutual concern, such as but not limited to:

  • Interventions/programs for health promotion/prevention
  • Interventions/programs leading to self-management in chronic conditions
  • Programs that target self or symptom management
  • Examine ways to enhance or implement sustainable health programs in community settings  

Sponsor: NIH

Letter of Intent: None

Application Deadline: Standard NIH Dates Apply (until May 8, 2017)


Translational Programs in Lung Diseases (P01)


This Funding Opportunity Announcement (FOA) invites submission of Program Project (P01) applications from institutions/organizations that will perform collaborative, translational research with the goal of using mechanistic research as the basis for the rational design of clinical applications to improve prevention, diagnosis and/or treatment of lung diseases and sleep disorders. 

Award Budget: Less than $1.75 million per year direct costs (exclusive of F&A costs associated with consortia) for a maximum of $8.75 million directs costs over a five-year project period.


Letter of Intent Due Date: 30 days prior to the application due date
Application Due Date: 5pm CT -  May 19, 2015; September 22, 2015, et al.

Grants to Enhance Applicability of Mouse Models for Translational & Oncologic Research

PAR-14-241 R01 Research Projects to Enhance Applicability of Mouse Models for Translational Research
PAR-14-240 R01 Research Project Grant
PAR-14-239 ​U24 Oncology Models Forum (Collaborative Agreement)

The purpose of this set of Funding Opportunity Announcements (FOAs) is to invite applications for projects to expand and improve the utility of mouse cancer and tumor models for translational research. The NCI supports many hypothesis-driven, mechanistic R01 projects that employ mice, or develop and use mouse cancer models or human-in-mouse tumor models for many aspects of oncology research.  However, the NCI has not previously supported projects devoted to ensuring that mice and mouse models used for translational research questions are appropriate for those purposes and that the models provide reliable and informative data for patient benefit.  Applications could propose to overcome limitations of mouse and human-in-mouse oncology models, define a new translational use of models or mouse genetics for unmet needs, advance standard practices for modeling human cancers and tumors in mice and for validating and credentialing models, or develop widely applicable tool strains or resources that enable cross-species comparisons.

Letter of Intent Due Date: Not Applicable
Application Due Date: Standard dates apply (until May 8, 2017 (except U24))




​​​​​​​​​​​​​
SHARPEN YOUR SCIENCE:

For any internal or external application:

You write the science, let the CCTS do the rest.  Contact ccts@uab.edu for more information.


Tip of the Week!

Write for an intelligent layperson – not just for other experts in your field.  It must be transparent that your proposal is responsive, significant, cognizant of the field and innovative in approach ​-- For more information, contact CCTS Research Commons today (ccts@uab.edu; 4.7442).​


UAB Policy when Number of Submissions is Limited by Sponsor

Some sponsors restrict the total number of applications submitted per institution, school, and/or discipline. When the sponsor's program guidelines stipulate a limit, an internal review process may be necessary to determine the applicant(s) or proposal(s) to represent UAB.​​  Please see these guidelines​.  If you have any questions, please contact ccts@uab.edu.